Kudo, MasatoshiMasatoshiKudoFinn, Richard SRichard SFinnQin, ShukuiShukuiQinHan, Kwang-HyubKwang-HyubHanIkeda, KenjiKenjiIkedaANN-LII CHENGVogel, ArndtArndtVogelTovoli, FrancescoFrancescoTovoliUeshima, KazuomiKazuomiUeshimaAikata, HiroshiHiroshiAikataLópez, Carlos LópezCarlos LópezLópezPracht, MarcMarcPrachtMeng, ZhiqiangZhiqiangMengDaniele, BrunoBrunoDanielePark, Joong-WonJoong-WonParkPalmer, DanielDanielPalmerTamai, ToshiyukiToshiyukiTamaiSaito, KenichiKenichiSaitoDutcus, Corina ECorina EDutcusLencioni, RiccardoRiccardoLencioni2023-01-122023-01-122023-0101688278https://scholars.lib.ntu.edu.tw/handle/123456789/627204Validated surrogate endpoints for overall survival (OS) are important for expediting the clinical study and drug-development processes. Herein, we aimed to validate objective response as an independent predictor of OS in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy.enlandmark analysis; lenvatinib; mRECIST; response status; surrogate endpoint[SDGs]SDG3journal article10.1016/j.jhep.2022.09.006363417672-s2.0-85142433601https://api.elsevier.com/content/abstract/scopus_id/85142433601